Business
American Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project
American Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project.
About this update from American Diversified Holdings Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n American Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project\r\n \r\n \r\n\r\n\r\nAmerican Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project\r\n\r\n\r\n\r\nNewsfile Corp.\r\n\r\n\r\nNewsfile Corp\r\n\r\n\r\nDel Mar, California--(Newsfile Corp. - July 14, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the San Diego based bio engineering firm ARETE BIOSCIENCES, Inc. has made strong progress on several fronts.\r\nArete Engineering team has reviewed all previous engineering schematics including patent filings and other intellectual property, incorporated The Food and Drug Administration's (FDA) recommendations into the design plans and created an indepth CAD plan for the next stage of development.\r\nThe next stage will include:\r\n\r\n Finalize the product design based on updated requirements\r\n Build a \"looks-like\" prototype suitable for a usability study with unbiased participants\r\n Provide an estimate to support this upcoming phase of development\r\n \r\nArete will be conducting an usability study including approximately ten participants to establish the wearability and comfort of the device as directed by the FDA.\r\nIt is anticipated that Arete will complete the project in the next 7 to 10 days.\r\nArete BioScience's team of scientists and biomechanical engineers have completed a review of GlucoGuard's foundational documentation including intellectual property, design schematics, and FDA application documentation. The team has devised a development protocol that will be initiated with the input and guidance of GlucoGuard's advisor Dr. Stephen Weber in order to facilitate the next step in the FDA approval process.\r\nMore news on the DEXCOM partnership progression, how GlucoGuard is utilizing Artificial Intelligence in predicting Hypoglycemia and other key issues will be publicized in the near term.\r\nABOUT ARETE BIOSCIENCES, Inc.\r\nArete BioSciences, Inc. (\"Arete\") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the h...